Krystal Biotech reports news on its commercial genetic-medicines business, led by VYJUVEK, a redosable gene therapy approved in the United States, Europe, and Japan for dystrophic epidermolysis bullosa. Company updates commonly cover VYJUVEK revenue and global commercialization, manufacturing and platform developments, and regulatory actions tied to its HSV-1-based gene delivery technology.
Recurring clinical and scientific updates address investigational programs including KB407 for cystic fibrosis, KB707 for advanced or metastatic non-small cell lung cancer, KB111 for Hailey-Hailey disease, KB803 for corneal abrasions in DEB patients, and additional HSV-1-based vectors. News also includes quarterly operating results, conference presentations, FDA designations, and investor-event participation.
Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in the BofA Securities 2024 Health Care Conference where Chairman and CEO Krish S. Krishnan will engage in a fireside chat and host investor meetings. The webcast of the presentation will be available on the Company's website.
Krystal Biotech, Inc. reported $45.3 million in net product revenue for 1Q 2024. The company is focused on delivering genetic medicines for rare diseases like Dystrophic Epidermolysis Bullosa. With a strong financial position and positive performance in clinical trials, Krystal Biotech is poised for growth. Key developments include progress with VYJUVEK, successful clinical studies in Japan, and ongoing trials for cystic fibrosis and alpha-1 antitrypsin deficiency treatments. The company also received FDA Fast Track Designation for inhaled KB707 for lung tumors. Financially, the company recorded $622.3 million in cash and investments with a net income of $0.9 million for 1Q 2024.
Krystal Biotech announced their participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting where they will present new preclinical data on their HSV-1 based vector platform for back of the eye gene delivery. The poster presentation will focus on localized delivery to the posterior of the eye, with details about the presenter, date, time, and abstract number. The poster will be available both at the conference and online on the Investor section of the Company's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.